Results 21 to 30 of about 669,728 (307)

Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s. [PDF]

open access: yes, 2016
Group 2 innate lymphoid cells (ILC2s) and type 2 helper T cells (Th2 cells) are the primary source of interleukin 5 (IL-5) and IL-13 during type 2 (allergic) inflammation in the lung.
Austen, K Frank   +5 more
core   +1 more source

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]

open access: yes, 2020
BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai   +13 more
core   +1 more source

Eosinophilia Associated With CD3−CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients

open access: yesFrontiers in Immunology, 2020
Background: Lymphocytic variant hypereosinophilic syndrome is characterized by marked over-production of eosinophilopoietic factor(s) by dysregulated T cells leading to eosinophil expansion.
Caroline Carpentier   +7 more
doaj   +1 more source

The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic

open access: yesНаучно-практическая ревматология, 2021
Objective. Currently, the issues of the effect of anti-B cell therapy or inhibitor of interleukin 5 on the risk of COVID-19 infecting and outcomes in patients with ANCA-associated vasculitis (AAV) has not been completely studied.
T. V. Beketova   +2 more
doaj   +1 more source

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

open access: yes, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,   +3 more
core   +1 more source

Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps [PDF]

open access: yes, 2019
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a signifcant impairment in quality of life.
Cavaliere, Carlo   +7 more
core   +1 more source

Role of a Th2 cytokine inhibitor in asthma treatment

open access: yesAllergology International, 2004
The airway wall of asthmatic patients is infiltrated with inflammatory cells, consisting chiefly of eosinophils and T lymphocytes. Among these T lymphocytes, Th2 cells are involved in the regulation of the IgE immune response and local allergic ...
Jun Tamaoki
doaj   +1 more source

Interleukin-5 and Interleukin-5 Receptor Polymorphism in Asthma

open access: yes, 2023
Asthma is a common chronic inflammatory disease of the airways of the lungs, in the world. It’s associated with type 2 cytokines interleukin-4, IL-5, and IL-13, which promote airway eosinophilia, bronchial hyperresponsiveness, mucus overproduction, and immunogloubulin E synthesis.
Maytham, Hameed, Raghdah   +2 more
openaire   +2 more sources

Impaired interferon-γ responses, increased interleukin-17 expression, and a tumor necrosis factor–α transcriptional program in invasive aspergillosis [PDF]

open access: yes, 2009
This article is available open access through the publisher’s website. Copyright @ 2009 Oxford University Press.Background - Invasive aspergillosis (IA) is the most common cause of death associated with fungal infection in the developed world ...
Armstrong-James, DP   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy